Study Describes Novel Model of Skin Cancer

Dec 09, 2009
Normal skin (Norm) with adjacent squamous cell carcinoma (Tumor). Credit: John T. Seykora, MD, PhD, University of Pennsylvania School of Medicine

(PhysOrg.com) -- Scientists at the University of Pennsylvania School of Medicine have developed a new model of skin cancer based on the knowledge that a common cancer-related molecule called Src kinase is activated in human skin-cancer samples.

“Our previous work demonstrated that Src kinases are activated in human squamous cell carcinomas of the skin. We modeled these observations by increasing the expression of the gene Fyn, a member of Src family of proteins, in mouse skin,” explains senior author John T. Seykora MD, PhD, assistant professor of Dermatology. In addition, prior work by the Seykora lab on a related protein called Srcasm, discovered by him in 2002, suggested that Srcasm may function as an anti-oncogene, a molecule that keeps others in check in order to control cell growth.

In this proof-of-principle study, published this month in Cancer Research, the authors found that genetically engineered mice expressing a K14-Fyn transgene develop precancerous lesions and invasive squamous cell carcinomas (SCCs) spontaneously in 5 to 8 weeks. Skin SCCs are the second most common form of cancer, with greater than 250,000 cases annually in the US, leading to approximately 2,500 deaths.

This study demonstrates that Fyn is a potent in skin. When Srcasm levels are raised in the mouse model, is dramatically inhibited showing that Srcasm functions as an anti-oncogene.

The findings highlight an important relationship between Fyn and Srcasm—Fyn encourages growth, while Srcasm inhibits it. “When this system malfunctions, it’s like stepping on the gas and taking off the brakes on cell growth,” explains Seykora. “Adding Srcasm back to the system lowers Fyn levels and restores order.”

Analysis of human skin tumor samples confirmed that Srcasm levels are decreased and Src kinase activity is increased. The authors conclude that one potential means of combating skin cancer would be to inhibit Src kinases and/or increase Srcasm levels.

This work may have broader relevance as Src kinases are one of the longest studied oncogenes and are activated in many types of human cancer, including colon and breast cancer. This study provides insight into how Src kinases are activated in human cancers. Further study of this model may provide insights into treating carcinomas that have increased Src kinase activity.

Future work will involve determining how Srcasm levels are decreased in skin tumors to promote cell growth. In addition, topical compounds will be tested using this model to determine if they may be useful in treating skin cancer in people.

Provided by University of Pennsylvania School of Medicine (news : web)

Explore further: Enzyme controlling metastasis of breast cancer identified

add to favorites email to friend print save as pdf

Related Stories

Deactivating a cancer growth promoter

Sep 25, 2008

Three enzymes called phosphatases that shut down a molecule called SRC-3 (steroid receptor coactivator 3) could provide a new pathway for fighting cancer, particularly tumors of the breast and prostate, said researchers at ...

New discovery raises doubts about current bladder treatment

Mar 25, 2009

Researchers at the University of Virginia Health System have found that one of the genes commonly thought to promote the growth and spread of some types of cancers is in fact beneficial in bladder cancer - a major discovery ...

Notorious cancer gene may work by destroying messenger

Mar 19, 2007

A new study suggests how a notorious cancer gene may contribute to tumor growth.The insight emerged from a long-running study of a protein called PMR1, the key player in an unusual mechanism that cells use to quickly stop ...

Protein 'switch' suppresses skin cancer development

Sep 08, 2008

The protein IKKalpha (IKKα) regulates the cell cycle of keratinocytes and plays a key role in keeping these specialized skin cells from becoming malignant, researchers at The University of Texas M. D. Anderson Cancer ...

Recommended for you

User comments : 0